Retrospective Cohort Study
Copyright ©The Author(s) 2023.
World J Gastroenterol. Dec 21, 2023; 29(47): 6111-6121
Published online Dec 21, 2023. doi: 10.3748/wjg.v29.i47.6111
Table 1 Baseline patient characteristics
Characteristic
All, n = 75
Age in yr, median [IQR]49 [36, 62]
Male/Female, n (%)45 (60.0)/30 (40.0)
Disease duration in yr, median [IQR]8 [5, 13]
Disease extent, n (%)
Extensive colitis45 (60.0)
Left-sided colitis24 (32.0)
Proctitis6 (8.0)
CAI by the Rachmilewitz index, median [IQR]0 [0, 1]
MES, n (%)
MES 043 (57.3)
MES 132 (42.7)
UCEIS, n (%)
UCEIS 039 (52.0)
UCEIS 117 (22.7)
UCEIS 213 (17.3)
UCEIS 36 (8.0)
UCCIS, median [IQR]0 [0, 6.7]
FC in mg/kg, median [IQR]174 [43, 810]
Medication used during the study, n (%)
Oral 5-ASA48 (64.0)
Suppository steroids2 (2.7)
Systemic steroids9 (12.0)
Immunomodulators23 (30.7)
Biologics30 (40.0)
Table 2 Receiver-operating characteristic analysis of fecal calprotectin and Ulcerative Colitis Colonic Index of Severity for predicting Mayo Endoscopic Subscore 0
Factor
FC
UCCIS
Cut-off value3856.6
AUC (95%CI)0.858 (0.770-0.946)0.987 (0.969-1.000)
PPV0.7930.992
NPV0.8040.994
Sensitivity0.7190.992
Specificity0.8040.985
Accuracy0.8000.947
Table 3 Comparison of accuracy of relapse prediction between fecal calprotectin levels, Ulcerative Colitis Colonoscopic Index of Severity, Mayo Endoscopic Subscore, and Ulcerative Colitis Endoscopic Index of Severity
Factor
Sensitivity
Specificity
PPV
NPV
Accuracy
FC ≥ 3230.5000.9330.8330.7370.760
UCCIS ≥ 10.20.7500.8980.6670.9300.867
MES 10.8330.7020.4690.9300.733
UCEIS ≥ 20.7220.8950.6840.9110.853